Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized study of methylprednisolone 1 mg/kg/day for grade I acute graft-versus-host disease
2008-000413-29Phase 3Completed
- Sponsor
- GITMO
- Start
- Jan 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by GITMO. Primary endpoint: Progression rate to acute graft-versus-host disease grade >1. Started Jan 2012; status: completed.
02
Drugs
methylprednisolone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2008-000413-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000413-29.